Clinical trials: Hyperphosphataemia
Hyperphosphatemia
BAY 77-1931 Long-term Extension From Phase II Study
A long-term study of BAY77-1931 (lanthanum carbonate) for hyperphosphatemia in patients undergoing hemodialysis
- Trial name
- NCT00769496
- Testing
- BAY 77-1931
- Where
- 14 sites in Japan
- Volunteers
- 145 people
- Sponsor
- Bayer
Chronic Renal Failure Patients With Hyperphosphataemia Receiving Hemodialysis
Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients
The purpose of this survey is to evaluate the safety and efficacy of long-term use of Kiklin® Capsules in actual clinical settings.
- Trial name
- NCT01901107
- Testing
- Kiklin capsules
- Where
- 8 sites in Japan
- Volunteers
- 1,078 people
- Sponsor
- Astellas Pharma Inc
Hyperphosphatemia Patients on Hemodialysis
A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
A phase 2, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis
- Trial name
- NCT06745518
- Testing
- TS-172
- Where
- Japan
- Volunteers
- 62 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Hyperphosphatemia
Long Term Treatment of End Stage Renal Disease Patients With Lanthanum Carbonate (Fosrenol)
Patients who have been treated with Fosrenol for a minimum of 12 consecutive weeks and are receiving dialysis will be followed for 5 years to compare mortality, bone fractures and incidence of selected morbidities to patients…
- Trial name
- NCT00567723
- Where
- 199 sites in United States
- Volunteers
- 2,105 people
- Sponsor
- Shire
Hyperphosphatemia, Dialysis
Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone
To measure lanthanum concentrations in bone in patients with hyperphosphatemia receiving dialysis
- Trial name
- NCT00767637
- Testing
- Lanthanum Carbonate (BAY77-1931)
- Where
- 2 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Bayer
Hyperphosphatemia, End Stage Renal Disease
Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
To evaluate the efficacy and safety of ferric citrate capsules for the treatment of hyperphosphatemia in patients with chronic kidney disease undergoing hemodialysis
- Conditions
- Hyperphosphatemia, End Stage Renal Disease, ESRD
- Trial name
- NCT03984760
- Testing
- Ferric Citrate, Sevelamer Carbonate
- Where
- 24 sites in China
- Volunteers
- 240 people
- Sponsor
- Panion & BF Biotech Inc.
Hyperphosphatemia, Chronic Kidney Disease
Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules
Phosphate binders are crucial to the control of elevated phosphate levels in patients with chronic kidney disease. With the new formulation of granules the pill burden of patients is sought to be reduced.
- Trial name
- OsvaRenNEW (NCT02027662)
- Testing
- Osvaren Granules, Osvaren film-coated tablets
- Where
- 11 sites in Germany
- Volunteers
- 61 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Chronic Kidney Disease Requiring Hemodialysis
PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
To investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia.
- Trial name
- NCT01521494
- Testing
- PA21
- Where
- Japan
- Volunteers
- 183 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Chronic Kidney Disease, Renal Dialysis
Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease and hyperphosphatemia patients on hemodialysis.
- Conditions
- Chronic Kidney Disease, Renal Dialysis, Renal Insufficiency, Hyperphosphatemia
- Trial name
- NCT00892749
- Testing
- ASP1585
- Where
- 4 sites in Japan
- Volunteers
- 248 people
- Sponsor
- Astellas Pharma Inc
Hyperphosphatemia Related to Chronic Kidney Disease
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
- Trial name
- NCT04523727
- Testing
- ferric citrate
- Where
- 14 sites in United States
- Volunteers
- 45 people
- Sponsor
- Keryx Biopharmaceuticals
Hyperphosphatemia
Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers
To compare the bioequivalence of calcium acetate oral solution vs. calcium acetate gelcaps in healthy volunteers with calcium citrate as a positive control.
- Trial name
- NCT00742820
- Testing
- Calcium Acetate Oral Solution 667 mg per 5 mL, Calcium Acetate 667 mg GelCaps, Calcium Citrate 950 mg Caplets
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Fresenius Medical Care North America
Chronic Kidney Disease Requiring Chronic Dialysis
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
This is a Phase 3, randomised, active controlled, multicentre study to investigate the safety and efficacy of PA21, a phosphate binder, for control of hyperphosphataemia in dialysis patients.
- Trial name
- NCT01324128
- Testing
- PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate, PA21-1 (1.25 g tablet containing 250 mg iron)
- Where
- 15 sites in United States, Austria and 13 more
- Volunteers
- 1,059 people
- Sponsor
- Vifor Pharma
Hyperphosphatemia Patients on Hemodialysis
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
A phase 3, randomized, placebo-controlled, double-blind study of TS-172 in hyperphosphatemia
- Trial name
- NCT06745531
- Testing
- TS-172 20~60 mg/day
- Where
- Japan
- Volunteers
- 101 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
This is a randomized, open-label study to evaluate different methods of initiating tenapanor therapy in CKD patients on dialysis with hyperphosphatemia, when they are either phosphate binder naïve or on phosphate binder therapy.
- Trial name
- OPTIMIZE (NCT04549597)
- Testing
- Tenapanor
- Where
- United States
- Volunteers
- 333 people
- Sponsor
- Ardelyx
Hyperphosphatemia, Inflammation
An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients
The purpose of the study is to determine whether an ingestion of a new renal multivitamin supplement can have a beneficial effect on bone and mineral adn inflammation issues related to patients on dialysis.
- Conditions
- Hyperphosphatemia, Inflammation, Renal Disease
- Trial name
- NCT00834301
- Testing
- Oral Multivitamin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Nephrian
Kidney Diseases, Renal Insufficiency
Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia
This is a randomized, dose-ranging, efficacy and tolerability study in chronic kidney disease patients with hyperphosphatemia on hemodialysis. Patient participation in the study is approximately 10 weeks in duration.
- Trial name
- NCT00358046
- Testing
- ILY101
- Where
- 18 sites in United States
- Volunteers
- 120 people
- Sponsor
- Ilypsa
Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia
PA21 Safety and Efficacy in Adult Chinese Subjects
This study evaluates the efficacy of PA21 in comparison with sevelamer carbonate (Renvela®) in lowering and maintaining serum phosphorus in adult Chinese subjects with CKD on dialysis after 12 weeks of treatment.
- Trial name
- NCT03644264
- Testing
- PA21, sevelamer carbonate
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
Hyperphosphatemia
Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
To investigate the safety of repeated administration of KHK7791 for 52 weeks while switching from a phosphate-binding agent to KHK7791 in Hemodialysis patients with hyperphosphatemia.
- Trial name
- NCT04771780
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 213 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hyperphosphatemia
To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder
The aim of the study is: To evaluate the tolerance of lanthanum polystyrene sulfonate powder in patients with end-stage renal disease (ESRD-HD) hyperphosphatemia with multiple doses and multiple doses； To evaluate the…
- Trial name
- NCT04440696
- Testing
- Lanthanum Polystyrene Sulphonate Powder, Lanthanum Carbonate 500 MG
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Grand Life Science (Liaoning) Co., Ltd.
Hyperphosphatemia
A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD
To evaluate the effect and safety of a switch from phosphate binders to KHK7791 to treat Hyperphosphatemia in patients on HD.
- Trial name
- NCT03831607
- Testing
- KHK7791
- Where
- Japan
- Volunteers
- 67 people
- Sponsor
- Kyowa Kirin Co., Ltd.